Found 119 clinical trials
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive
Aim of this study is to evaluate Daratumumab effect on MRD-positive patients with Multiple Myeloma (MM) who achieved >VGPR after any therapy (ASCT, VMP, Rev-Dex). Daratumumab 16 mg/kg administered at weekly intervals for 8 weeks, then every 2 weeks for an additional 16 weeks, will be given to 50 MM …
- 3 views
- 22 Jan, 2021
- 1 location
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients. The only potential curative treatment remains allogeneic Hematopoietic stem cell transplant (HSCT), as shown by our cohort of 92 newly diagnosed …
- 65 views
- 05 Feb, 2021
- 3 locations
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies). PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus host disease (GVHD). Hematopoietic cells are found in the bone marrow …
- 0 views
- 01 Nov, 2021
- 1 location
Chemotherapy and G-CSF for Mobilization
This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in myeloma patients.
- 4 views
- 12 Aug, 2021
- 1 location
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
Multiple myeloma (MM) is a common malignant hematology disease. The development of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) significantly improved the survival of MM patients. IMiDs have multiple effects in MM therapy. Except for direct cytotoxicity, IMiDs also play a variety of immune regulatory roles. Lenalidomide, a kind of …
- 5 views
- 23 Jan, 2021
- 1 location
Study of Pomalidomide Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
The purpose of this study is to evaluate the efficacy and safety of ixazomib, oral dexamethasone and in patients with relapsed multiple myeloma who have received lenalidomide.
- 0 views
- 28 Aug, 2021
- 1 location
Belantamab Mafodotin Lenalidomide and Daratumumab for the Treatment of Relapsed Refractory or Previously Untreated Multiple Myeloma
This phase I/II trial studies the best dose and effect of belantamab mafodotin given together with lenalidomide and daratumumab in treating patients with multiple myeloma that has come back (relapsed), does not respond to treatment (refractory) or for which the patient has not received treatment in the past (previously untreated). …
- 0 views
- 18 Oct, 2021
- 1 location
Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, but not well understood complication to treatment with chemotherapy. In this study the investigators will investigate a novel method for early detection of CIPN and compare it to other methods in patients treated for haematological cancers.
- 0 views
- 25 Jan, 2021
- 1 location
Diagnostic of Chemotherapy Induced Neuropathy in Children
The purpose of this study is to determine the diagnostic accuracy of a newly developed tool (Electrochemical Skin Conductances (ESC) measurement) easy-to-perform, non-invasive, highly reproductible and not requiring specific training, to identify pediatric chemotherapy-induced-peripheral-neuropathies (CIPN). CIPN are a frequent (20 to 75% depending on the drug), early and potentially severe …
- 0 views
- 26 Jan, 2021
- 1 location
Non-interventional Study of Kyprolis in Combination With Revlimid and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex and Dexamethasone in Multiple Myeloma Patients
The objective of this non-interventional study (NIS) is to evaluate patients' adherence and persistence to carfilzomib therapy in combination with lenalidomide and dexamethasone or in combination with dexamethasone alone or in combination with daratumumab and dexamethasone in adult patients with multiple myeloma (MM) who have received at least one prior …
- 16 views
- 25 Apr, 2021
- 1 location